Bisacodyl [4,4’-diacetoxy-diphenyl-(pyridyl-2)-methane], a diphenylmethane derivate stimulant laxative, has been available as a laxative since 1952. It is an effective and well-tolerated treatment for patients with constipation. It improves bowel function, constipation-related symptoms, and disease-related quality of life (QOL). It has been used as a first-line laxative for functional constipation management and, more recently, used to facilitate bowel preparation before investigational procedures (i.e., colonoscopy, sigmoidoscopy), surgery, or pharmacologic provocation during colon manometry. Bisacodyl is effective when administered to patients with neuropathy. Bisacodyl appears superior to the other drugs for changing the number of bowel movements per week. Its effect occurs in the large intestine within 6 to 12 hours after ingestion by mouth and within 15 to 60 minutes after rectal administration. Bisacodyl classifies as having level 4 evidence regarding its safety and efficacy for chronic constipation in a systematic review. In 2005, The American College of Gastroenterology Chronic Constipation Task Force stated that there are insufficient data to make a recommendation about the efficacy of stimulant laxative for the management of chronic constipation.
Bisacodyl’s target of action is the gastrointestinal tract. Absorption from the GI tract is minimal because its formulation is a coated tablet, which is resistant to destruction in the stomach and small intestine and thus achieves transit to the colon in its intact form. It then dissolves in the colon and ensures a laxative effect after oral intake. Intestinal deacetylase and bacterial enzymes hydrolyze bisacodyl to a deacetylated active metabolite, bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which stimulates the intestinal mucosa, causing peristalsis, which is responsible for the laxative action. BPHM has a dual activity in the colon, including an anti-absorptive-secretory effect and a direct prokinetic effect by stimulating parasympathetic nerve endings in the colonic mucosa. It acts locally in the large bowel by stimulating the colon’s myoelectrical and motor activity and intestinal secretion, thus enhancing colon’s motility, reducing overall colonic transit time, and increasing the water content of the stool. Ratnaike et al. demonstrated that bisacodyl impairs fluid absorption by activating adenylate cyclase in the small intestinal enterocytes which increases the level of cyclic AMP, and causes the active secretion of Cl- and HCO3-, passive efflux of Na+, K+ and water and inhibition of Na+ and Cl- absorption into the enterocyte. Bisacodyl may also exhibit its laxative effect by decreasing the expression of aquaporin 3 (AQP3) in the colon, therefore inhibiting water transfer from the intestinal tract to the vascular side of the cells. Bassotti et al. investigated the effect of a 10 mg bisacodyl solution and found that about 90% of patients with slow transit constipation showed motor response characterized by one or more high amplitude propagated contractions (HAPCs). Min et al. conducted a study showing that bisacodyl increases sigmoid colon longitudinal muscle tone through direct action on the smooth muscle, but not in the colonic circular muscle, and suggest that bisacodyl could be effectively administered to manage constipation in patients with neuropathy because bisacodyl improves the spatiotemporal-coordinated pattern of HAPCs.
Bisacodyl administration can be via oral or rectal routes. In adults, bisacodyl is given in doses of 5 to 10 mg tablet daily administered at night or bedtime, because it works within 6 to 12 hours following administration when taken orally so that the therapeutic effect will occur in the morning. It also can be given in 10 mg as an enema or suppository administered in the morning because bisacodyl will work within 15 to 60 minutes following rectal administration. Doses of 10 to 20 mg are given by mouth for complete bowel evacuation, followed by 10 mg as a suppository the next morning. In children from 3 to 10 years old, bisacodyl oral or rectal is given in doses of 5 mg per day in one dose at night. Ten years old or older can be given in up to 10 mg per day in one dose a day at night. Continued use of bisacodyl may result in a decrease in its efficacy, which occurs because bisacodyl increases the production of PGE2, which decreases the expression of AQP3, and the effectiveness of compounds that decrease AQP3 expression in the colon, which becomes reduced by continued use.
The most common adverse effects seen in more than 5 percent of patients taking bisacodyl are diarrhea, abdominal pain (mostly in the upper abdomen), and headache. Although it is unlikely that chronic use of bisacodyl is harmful to the colon, it could induce abdominal discomfort and cramping pain. But, it is generally well-tolerated, safe, and effective for adults and children. Joo JS et al. showed that 45 percent of patients using bisacodyl or other laxatives (phenolphthalein, senna, and casanthranol) more than three times per week for one year or longer (this defined as chronic stimulant laxative use) had subsequent radiographic changes of colonic redundancy and dilation of colon, with loss of haustral markings which did not occur in the control groups. It may suggest that these agents cause a neuronal injury or damage to colonic longitudinal musculature. Myenteric plexus or smooth muscle damage due to stimulant laxatives is rare, and it is unclear if this is due to constipation or laxative use. The association between stimulant laxatives and colorectal neoplasm in humans remains inconclusive, and the data is lacking in human studies, but in vitro studies showed that bisacodyl was found to induce proliferative epithelial lesions, including a transitional-cell carcinoma, but only in the urinary bladder epithelium of rats. Other side effects of bisacodyl include muscle weakness, nausea, vomiting, anorexia, and rectal irritation. It also has correlations with salt overload, hypokalemia, and protein-losing entropy. Ajani et al. reported a case that showed that bisacodyl correlates with colonic ischemia (CI), but the explanation for bisacodyl-induced CI is not clear. Rectal administration of bisacodyl may cause rectal mucosa irritation and a sensation of burning and mild proctitis. Bisacodyl has some interactions with other drugs such as digoxin, antacids, and histamine H2-receptor antagonist. Wang et al. conclude that bisacodyl interferences the absorption of digoxin, resulting in the reduction of the serum digoxin concentration. Antacid and histamine H2-receptor antagonists cause the enteric coating to dissolve too rapidly and may result in gastric or duodenal irritation when administered within one hour of bisacodyl tablets.
Bisacodyl's primary indication is adults or children with constipation, especially chronic constipation. Bisacodyl is contraindicated in patients with acute gastrointestinal diseases such as appendicitis or diarrhea, with ileus or suspected bowel obstruction, bowel perforation, colitis, toxic megacolon, have severe dehydration, electrolyte imbalance (i.e., hypokalemia, hyponatremia, metabolic alkalosis or acidosis), or are allergic or hypersensitive to bisacodyl. Rectal administration of bisacodyl suppositories is also a contraindication in the patient who has inflammation or ulcer in the distal colon (ulcerative proctitis) and/or anal fissures.
Bisacodyl becomes deacetylated in the colon to its active metabolite. Its metabolite conjugates to the mono-glucuronide in the wall of the intestine or liver.  Bisacodyl’s absorption from the gastrointestinal tract is minimal. Therefore only a small amount of bisacodyl’s absorbed metabolite gets excreted in the urine as the glucuronide. There was no correlative relationship found between the plasma level of the metabolite and the laxative effect, suggesting that systemic absorption was not a requirement for the laxative action, and the effect of bisacodyl was subject to local mediation. Monitoring of bisacodyl's metabolite is possible in human urine, serum, and stool within 24 hours after ingestion. A serum electrolyte test is necessary when the patient is taking bisacodyl and shows symptoms of acid/base disturbances. Procedures used to analyze bisacodyl's metabolites are gas chromatography-mass spectrometry (GC-MS) and liquid chromatography.  The concentrations of bisacodyl diphenol, a metabolite of bisacodyl, in the patient's urine and serum were determined by using bisphenol A as the internal standard.
Overdosing of bisacodyl can induce diarrhea, which leads to electrolyte disturbances, including hypokalemia, hypocalcemia, metabolic acidosis, or alkalosis, which then may also produce vomiting and muscle weakness. Short-term use (3 days) of the recommended dose does not show any effect on serum electrolytes. A case report of chronic abuse of bisacodyl in a female patient showed a frequent and repetitive formation of urinary calculi with rapid double J stent encrustation. The treatment of laxative abuse is to cease the causative agent; this becomes challenging because constipation may occur again after stopping this drug, leading to patient distress. Bisacodyl is not recommended for use for more than four weeks due to harmful long-term colonic effects and possible carcinogenic risk of stimulant laxatives; epidemiological studies investigating its effects and safety over longer terms are warranted.
Constipation is a common disease that affects children and adults, especially in the elderly. Unmanaged constipation can progress to fecal impaction, which further impairs patients' quality of life and increases health-care costs. Constipation is one of the most prevalent outpatient diagnoses among gastrointestinal disorders. There are many pharmacologic agents for constipation, including over-the-counter (OTC) laxative products, rectal suppositories, and enemas. Oral products can classify as bulking agents, stool softeners, stimulant laxatives, and osmotic laxatives. It is challenging because there are no accepted guidelines about choosing, which is the best agent. The clinician should discuss all problems with the patient and coordinate with nurses or the caregiver to maximize the quality of service, thus increasing the patient's quality of life. The provider should consider all risks and benefits of using a laxative, especially a bisacodyl, in the management of constipation to minimalize the adverse effect. Besides using bisacodyl as a stimulant laxative, it is also essential to focus on individual therapy based on the symptoms and pathophysiology of the patient's disease and make a better follow-up to improve the outcome of this disorder. Pharmacists need to be engaged with both the patient, nursing staff, and the clinician, as these products are available OTC, and the burden of counseling and making recommendations may fall 100% to the pharmacist. The pharmacist should contact the patient's physician if there are any concerns over the patient's use of bisacodyl. Nurses should also understand the ramifications and potential adverse effects of these agents, and take a thorough medication history, including OTC agents, so the treating clinician has a clearer picture of the patient's case. This approach represents the type of collaborative interprofessional team approach that is necessary to drive patient outcomes to their optimal result. [Level 5]
Despite being used for symptomatic relief, laxatives are also misused by individuals who suffer from eating disorders like anorexia nervosa or bulimia, individuals who engaged in certain types of athletic training, including sports with set weight limits, and surreptitious laxative abusers who use the drugs to cause factitious diarrhea and may have a factitious disorder. The first step in treating laxative misuse is to determine what may be promoting the behavior. The individual who misuses the laxative has to stop the stimulant laxatives and replace them with osmotic supplements utilized to establish regular bowel movements. Education and further treatment are required to maintain a healthy bowel program. Referral for psychiatric treatment is essential in the case of eating disorders such as bulimia or anorexia nervosa to lessen the reliance on laxatives as a method to alter weight and shape.
|||Kamm MA,Mueller-Lissner S,Wald A,Richter E,Swallow R,Gessner U, Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2011 Jul; [PubMed PMID: 21440672]|
|||Kienzle-Horn S,Vix JM,Schuijt C,Peil H,Jordan CC,Kamm MA, Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study. Alimentary pharmacology [PubMed PMID: 16669963]|
|||Min YW,Ko EJ,Kim JH,Lee JY,Kim HC,Lee WY,Rhee PL, Increased Tone of the Human Colon Muscle by Bisacodyl In Vitro. Journal of neurogastroenterology and motility. 2018 Apr 30; [PubMed PMID: 29605986]|
|||Luthra P,Camilleri M,Burr NE,Quigley EMM,Black CJ,Ford AC, Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. The lancet. Gastroenterology [PubMed PMID: 31474542]|
|||Kienzle-Horn S,Vix JM,Schuijt C,Peil H,Jordan CC,Kamm MA, Comparison of bisacodyl and sodium picosulphate in the treatment of chronic constipation. Current medical research and opinion. 2007 Apr; [PubMed PMID: 17407625]|
|||Manabe N,Cremonini F,Camilleri M,Sandborn WJ,Burton DD, Effects of bisacodyl on ascending colon emptying and overall colonic transit in healthy volunteers. Alimentary pharmacology [PubMed PMID: 19678812]|
|||An evidence-based approach to the management of chronic constipation in North America. The American journal of gastroenterology. 2005; [PubMed PMID: 16008640]|
|||Ewe K,Hölker B, [The effect of a diphenolic laxative (Bisacodyl) on water- and electrolyte transport in the human colon (author's transl)]. Klinische Wochenschrift. 1974 Sep 1; [PubMed PMID: 4449188]|
|||Noergaard M,Traerup Andersen J,Jimenez-Solem E,Bring Christensen M, Long term treatment with stimulant laxatives - clinical evidence for effectiveness and safety? Scandinavian journal of gastroenterology. 2019 Jan; [PubMed PMID: 30700194]|
|||Hervé S,Savoye G,Behbahani A,Leroi AM,Denis P,Ducrotté P, Results of 24-h manometric recording of colonic motor activity with endoluminal instillation of bisacodyl in patients with severe chronic slow transit constipation. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. 2004 Aug; [PubMed PMID: 15305994]|
|||Ewe K, Effect of bisacodyl on intestinal electrolyte and water net transport and transit. Perfusion studies in men. Digestion. 1987; [PubMed PMID: 3678638]|
|||Ratnaike RN,Jones TE, Mechanisms of drug-induced diarrhoea in the elderly. Drugs [PubMed PMID: 9789728]|
|||Ikarashi N,Baba K,Ushiki T,Kon R,Mimura A,Toda T,Ishii M,Ochiai W,Sugiyama K, The laxative effect of bisacodyl is attributable to decreased aquaporin-3 expression in the colon induced by increased PGE2 secretion from macrophages. American journal of physiology. Gastrointestinal and liver physiology. 2011 Nov; [PubMed PMID: 21868635]|
|||Bassotti G,Chiarioni G,Germani U,Battaglia E,Vantini I,Morelli A, Endoluminal instillation of bisacodyl in patients with severe (slow transit type) constipation is useful to test residual colonic propulsive activity. Digestion. 1999 Jan-Feb; [PubMed PMID: 9892801]|
|||Xing JH,Soffer EE, Adverse effects of laxatives. Diseases of the colon and rectum. 2001 Aug; [PubMed PMID: 11535863]|
|||Wald A, Is chronic use of stimulant laxatives harmful to the colon? Journal of clinical gastroenterology. 2003 May-Jun; [PubMed PMID: 12702977]|
|||Joo JS,Ehrenpreis ED,Gonzalez L,Kaye M,Breno S,Wexner SD,Zaitman D,Secrest K, Alterations in colonic anatomy induced by chronic stimulant laxatives: the cathartic colon revisited. Journal of clinical gastroenterology. 1998 Jun; [PubMed PMID: 9649012]|
|||Portalatin M,Winstead N, Medical management of constipation. Clinics in colon and rectal surgery. 2012 Mar; [PubMed PMID: 23449608]|
|||Soufi-Afshar I,Moghadamnia A,Bijani A,Kazemi S,Shokri-Shirvani J, Comparison of pyridostigmine and bisacodyl in the treatment of refractory chronic constipation. Caspian journal of internal medicine. 2016 Winter [PubMed PMID: 26958328]|
|||Alikiaii B,Majedi MA,Hashemi ST,Kiani M, Comparing the Efficacy of Two Drugs Senalin and Bisacodyl in Treatment of Constipation in Intensive Care Units' Patients. Advanced biomedical research. 2019 [PubMed PMID: 30993087]|
|||Ajani S,Hurt RT,Teeters DA,Bellmore LR, Ischaemic colitis associated with oral contraceptive and bisacodyl use. BMJ case reports. 2012 Jul 25 [PubMed PMID: 22843752]|
|||Wang DJ,Chu KM,Chen JD,Tarn YH,Su DJ, [Drug interaction between digoxin and bisacodyl]. Journal of the Formosan Medical Association = Taiwan yi zhi. 1990 Oct [PubMed PMID: 1981783]|
|||Wickham RJ, Managing Constipation in Adults With Cancer. Journal of the advanced practitioner in oncology. 2017 Mar; [PubMed PMID: 29900023]|
|||Kudo K,Miyazaki C,Kadoya R,Imamura T,Jitsufuchi N,Ikeda N, Laxative poisoning: toxicological analysis of bisacodyl and its metabolite in urine, serum, and stool. Journal of analytical toxicology. 1998 Jul-Aug; [PubMed PMID: 9681329]|
|||Wu WJ,Huang CH,Chiang CP,Huang CN,Wang CN, Urolithiasis related to laxative abuse. Journal of the Formosan Medical Association = Taiwan yi zhi. 1993 Nov; [PubMed PMID: 7910057]|
|||Bashir A,Sizar O, Laxatives 2019 Jan; [PubMed PMID: 30725931]|
|||Roerig JL,Steffen KJ,Mitchell JE,Zunker C, Laxative abuse: epidemiology, diagnosis and management. Drugs. 2010 Aug 20 [PubMed PMID: 20687617]|